questionText: To ask the Secretary of State for Health and Social Care, what recent progress his Department has made on implementing a joint process between NICE and the MHRA for the licensing and appraisal of medicines; and whether the licensing and appraisal of the BREAKWATER treatment protocol for patients with BRAF-mutated bowel cancer will follow this pathway.
answerText: The National Health Service in England is legally required to fund medicines in line with National Institute for Health and Care Excellence’s (NICE) recommendations. Current treatment options for BRAF-mutated colorectal cancer depend on the stage of the d...
heading: NHS: Drugs